The Editorial on the Research Topic

A Revised Approach to the Pathogenesis and Diagnosis of Myelodysplastic Syndromes With Therapeutic Implication
In 1938, Cornelius Packard Rhoads and his colleague William Halsey Barker from the Hospital of the Rockefeller Institute for Medical Research in New York described the first cases of what they termed "refractory anemia" in patients with acquired anemia and refractory to treatment with iron and liver extract. Since then the most common method of investigation has been the cytological evaluation of the bone marrow (BM) aspirates [reviewed in Ref. (1) ]. Over time, it has been shown that this method is highly subjective and dependent on the pathologist's experience, and that it cannot detect the disease in the early stages.
For these reasons, in 2001 when in Blood (2) Maryalice Stetler-Stevenson published the first panel for multicolor flow-cytometry (MFC) evaluation of BM aspirates in cytopenic patients with suspected myelodysplastic syndromes (MDS), it was first welcomed as a major step forward. However, the benefits of applying this method have proven to be limited, despite the development and the improvement of various scoring systems [e.g., Kern score (3), Ogata score (4), Red score (5), etc.]. The recently published WHO classification stipulates that MFC findings alone are not sufficient to establish a primary diagnosis of MDS in the absence of conclusive morphological and/or cytogenetic data (6) .
However, recent years have seen advances in MDS diagnosis. Emerging technologies in molecular biology, such as next-generation sequencing, have enabled identification of mutations associated with MDS (7) and of the molecular basis for resistance to azacitidine therapy (8) . In addition, studies exploring the BM microenvironment have shown that inflammation is the underlying mechanism for the medullary abortion of hematopoietic stem progenitor cells (HSPC) and that the immune-mediated mechanism is responsible for the clonal evolution of the disease (reviewed 
